Assoc. Prof. Dr. Shi-liang Huang | Tumor | Best Researcher Award
Sun Yat-sen University | China
AUTHOR PROFILE
🧑🔬 DR. SHI-LIANG HUANG
Associate Professor in Medicinal Chemistry
Sun Yat-sen University, People’s Republic of China
🎯 OBJECTIVE
Dedicated Associate Professor specializing in Medicinal Chemistry, with a passion for driving innovation in drug discovery and development, focusing on the tumor microenvironment and the heat shock response.
📘 EARLY ACADEMIC PURSUITS
Dr. Huang’s academic journey began with a solid foundation in Chemistry and Biochemistry, laying the groundwork for a distinguished career. After excelling in undergraduate studies, Dr. Huang pursued advanced degrees in Medicinal Chemistry, demonstrating exceptional aptitude for research and innovation.
Key achievements during this phase include:
- Master’s Thesis: Groundbreaking work on natural product derivatives for therapeutic applications.
- Doctoral Research: Advanced studies on the mechanisms of small molecules in altering biochemical pathways.
🏢 PROFESSIONAL ENDEAVORS
As an Associate Professor at Sun Yat-sen University, Dr. Huang has significantly contributed to the university’s reputation as a leading institution in medicinal research. His professional journey is marked by:
- Leading Interdisciplinary Teams: Collaborating with experts in oncology, biochemistry, and computational modeling.
- Research Innovation: Pioneering techniques in synthesizing inhibitors targeting heat shock proteins (HSPs) and heat shock factor 1 (HSF1).
- Teaching Excellence: Mentoring students in natural medicinal chemistry and drug design methodologies.
🧪 CONTRIBUTIONS AND RESEARCH FOCUS
Dr. Huang’s work revolves around integrating bioorganic chemistry with tumor microenvironment studies to innovate cancer therapies. Key contributions include:
- Medicinal Chemistry: Developing novel molecules with high specificity for cancer-related targets.
- Natural Product Exploration: Isolating and modifying natural compounds to enhance their therapeutic potential.
- Heat Shock Response Modulation: Designing inhibitors to disrupt HSF1 and HSP pathways, which are critical in cancer cell survival under stress.
- Tumor Microenvironment Studies: Investigating how microenvironmental factors influence drug efficacy.
🌟 IMPACT AND INFLUENCE
Dr. Huang’s research has had a profound impact on the scientific community and beyond:
- Published Works: Author of numerous peer-reviewed articles in high-impact journals.
- Citations and Recognition: Garnered widespread academic citations, reflecting the influence and applicability of his research.
- Collaboration and Leadership: Actively involved in global collaborations, enhancing the translational impact of his findings.
📊 ACADEMIC CITATIONS AND METRICS
Dr. Huang’s academic metrics underscore his scholarly contributions:
- H-Index: Demonstrates significant citation impact in medicinal chemistry and oncology.
- Published Articles: Over 50 research papers, including breakthroughs in bioorganic and natural medicinal chemistry.
- Research Grants: Secured funding for multiple national and international projects.
🏆 LEGACY AND FUTURE CONTRIBUTIONS
As a visionary in drug discovery, Dr. Huang aspires to expand his research impact by:
- Advancing precision medicine approaches tailored to the tumor microenvironment.
- Developing next-generation inhibitors targeting stress-response proteins in cancer therapy.
- Mentoring the next wave of researchers in innovative medicinal chemistry.
🌏 CONCLUSION
Dr. Shi-liang Huang embodies a blend of academic rigor, research innovation, and educational leadership. His contributions continue to shape the future of medicinal chemistry, with a legacy that inspires collaboration, discovery, and impactful solutions in cancer therapy.
- A Novel HSF1 Activator Ameliorates Non-Alcoholic Steatohepatitis by Stimulating Mitochondrial Adaptive Oxidation
- Authors: Rao, Y.; Li, C.; Hu, Y.-T.; Ye, J.-M.; Huang, Z.-S.
- Journal: British Journal of Pharmacology
- Year: 2022
- Design, Synthesis, and Evaluation of New Sugar-Substituted Imidazole Derivatives as Selective c-MYC Transcription Repressors Targeting the Promoter G-Quadruplex
- Authors: Li, M.-L.; Yuan, J.-M.; Yuan, H.; Chen, S.-B.; Huang, Z.-S.
- Journal: Journal of Medicinal Chemistry
- Year: 2022
- Discovery of Quinacrine as a Potent Topo II and Hsp90 Dual-Target Inhibitor, Repurposing for Cancer Therapy
- Authors: Pan, X.; Mao, T.-Y.; Mai, Y.-W.; Huang, Z.-S.; Huang, S.-L.
- Journal: Molecules
- Year: 2022
- Discovery of a Novel G-Quadruplex and Histone Deacetylase (HDAC) Dual-Targeting Agent for the Treatment of Triple-Negative Breast Cancer
- Authors: Jiang, X.-C.; Tu, F.-H.; Wei, L.-Y.; Chen, S.-B.; Huang, Z.-S.
- Journal: Journal of Medicinal Chemistry
- Year: 2022
- Design and Synthesis of Bouchardatine Derivatives as a Novel AMP-Activated Protein Kinase Activator for the Treatment of Colorectal Cancer
- Authors: Xu, Y.-H.; Hu, Y.-T.; Xu, S.-M.; Chen, S.-B.; Huang, Z.-S.
- Journal: Journal of Medicinal Chemistry
- Year: 2023